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Abstract Cushing’s disease is a rare chronic disease
caused by a pituitary adenoma, which leads to excess
secretion of adrenocorticotropic hormone (ACTH). The
over-production of ACTH leads to hyperstimulation of the
adrenal glands and a chronic excess of cortisol, resulting in
the signs and symptoms of a severe clinical state (Cush-
ing’s syndrome) that leads to significant morbidity, nega-
tive impacts on the patient’s quality of life, and, if
untreated, increased mortality. The management of patients
with Cushing’s disease is complicated by the heterogeneity
of the condition, with signs and symptoms that overlap
with those of other diseases, and high subclinical incidence
rates. Controversies surrounding the tests used for screen-
ing and identifying patients with Cushing’s disease add to
the challenge of patient management. Surgical intervention
to remove the adenoma is the first-line treatment for
patients with Cushing’s disease, but medical therapies are
useful in patients who relapse or are unsuitable for surgery.
The recent introduction of pasireotide, the first pituitary-
directed medical therapy, expands the number of treatment
options available for patients with Cushing’s disease. This
state-of-the-art review aims to provide an overview of the
most recent scientific research and clinical information
regarding Cushing’s disease. Continuing research into
improving the diagnosis and treatment of Cushing’s disease
will help to optimize patient management.
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Introduction
Cushing’s disease is a severe clinical condition caused by a
pituitary adenoma hypersecreting adrenocorticotropic hor-
mone (ACTH) [1]. The permanently high levels of ACTH
lead to a chronic over-production of cortisol by the adrenal
glands, known as Cushing’s syndrome, with deleterious
effects on most tissues of the body. Cushing’s disease
accounts for the majority of cases of endogenous chronic
hypercortisolism; other causes include extrapituitary
tumors that secrete ACTH or corticotropin-releasing hor-
mone (CRH), adrenal adenoma or carcinoma, and adrenal
hyperplasia or dysplasia [1, 2].
Cushing’s disease is a rare condition, with an annual
incidence reported of 1.2–1.7 cases per million population
[3, 4] and a prevalence of 29.1 per million population [4].
However, the incidence of Cushing’s disease is high and
unfortunately still undiagnosed in some groups of patients,
such as those with poorly controlled diabetes, osteoporotic
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and relatively young women and men, and patients with
hypertension resistant to treatment [5–7]. As such, the
European Society of Endocrinology recommends investi-
gation for Cushing’s disease in patients presenting these
features at an unusual (young) age [8].
The heterogeneity of Cushing’s disease, the overlapping
of signs and symptoms with those of other disorders, the
need for differential diagnosis, the variety of biochemical
tests and imaging techniques available for diagnosis, and
questions surrounding how to better define response and
remission all contribute to the challenges physicians face in
optimizing patient management, despite ongoing advances
in diagnosis and treatment. Thus, a multidisciplinary team
of neurosurgeons, endocrinologists, and radiation oncolo-
gists, as well as an individualized patient approach, is
recommended for the management of Cushing’s disease
[9–19].
The first-line treatment for Cushing’s disease is trans-
sphenoidal surgery (TSS) to remove the adenoma, but
initial surgery frequently fails [2, 13]. Although radio-
therapy is an option if initial TSS is unsuccessful, the
effects of radiotherapy may only become apparent after
many years [20] and the intervention may be followed by
side effects, such as pituitary deficiency or failure, as well
as damage to the optic nerve because of the frequent need
of traditional approaches [21, 22]. Medical therapy can also
be useful in cases of surgical failure, but some of the drugs
in use have limited effects or are not approved for use in
treating Cushing’s disease [13, 23]. Pasireotide (Signifor;
Novartis AG, Basel, Switzerland), the first pituitary-direc-
ted medical therapy, was recently approved in the Euro-
pean Union and in the US for treating adult patients with
Cushing’s disease for whom surgery is not an option or for
whom surgery has failed. Its long-term effectiveness in
treating the symptoms of Cushing’s disease has been
shown in phase III trials [24, 25]. This state-of-the-art
review aims to provide an overview of the most recent
scientific research and clinical information regarding
Cushing’s syndrome, with an overall focus on Cushing’s
disease.
Pathophysiology and etiology of Cushing’s disease
Corticotrophic adenomas secreting ACTH are the most
common cause of endogenous Cushing’s syndrome,
accounting for approximately 70 % of cases [2]. The
increased ACTH secreted by the tumor acts on the adrenal
glands to stimulate increased cortisol production, which in
turn leads to the variety of signs and symptoms of Cush-
ing’s disease (Fig. 1). In most cases, the tumors are benign
and slow growing. Microadenomas (B10 mm in diameter)
are found in [90 % of cases, whereas macroadenomas
([10 mm in diameter) are less common (\10 % of cases).
As discussed below, the size of the tumor can influence
treatment outcomes.
The biochemical relationships involved in the hypo-
thalamus—pituitary—adrenal axis are such that hypercor-
tisolism leading to Cushing’s syndrome can also be caused
by extrapituitary tumors that secrete ACTH or CRH,
adrenal adenomas or carcinomas, and adrenal hyperplasia
or dysplasia [2]. Furthermore, several genetic alterations
have also been identified as contributing to sporadic cor-
ticotropinoma formation, including alterations to
PRKAR1A (encoding a cAMP-dependent protein kinase A
subunit), PDE11A (encoding a cyclic nucleotide signal
transducer), and PDE8B (encoding a cyclic nucleotide
phosphodiesterase) [26, 27]. Finally, aberrant stimulation
of steroidogenesis in ACTH-independent macronodular
adrenal hyperplasia and in some unilateral adenomas can
be driven by ectopic receptors such as those for glucose-
dependent insulinotropic peptide or gastric inhibitory
polypeptide, b-adrenergic receptors, serotonin, and proba-
bly angiotensin II receptor. However, it can also result
Fig. 1 Signs and symptoms of Cushing’s disease
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from increased expression or altered activity of eutopic
receptors such as those for vasopressin, luteinizing hor-
mone/human chorionic gonadotropin [28].
Morbidity and mortality of Cushing’s disease
Cushing’s disease is a serious condition associated with
significant morbidity and severe impacts on patients’
quality of life [29–31]. Although the tumors causing the
disease are slow growing, the efficient secretion of ACTH
means that clinical features manifest before the tumor has
grown large. These include easy bruising, peripheral
edema, facial plethora, proximal myopathy, purple striae,
weight gain, and growth retardation or delayed puberty in
children [32]. In addition, due to the prolonged exposure to
elevated cortisol levels, other features may manifest,
including severe fatigue, hypokalemia, hypertension,
depression and cognitive impairment, hyperpigmentation,
sexual/menstrual dysfunction, hirsutism, acne, osteoporosis
and bone fractures, kidney stones, and susceptibility to
opportunistic infections (Fig. 1) [33–40]. Patients present-
ing pituitary adenomas frequently experience impairment
of the gonadotropic axis resulting in impaired fertility [41].
Furthermore, the effects of Cushing’s disease include car-
diovascular complications [42–45], as well as metabolic
disturbances that can result in fat tissue redistribution and
obesity [42, 46–48]. In a recent population-based cohort
study, patients with Cushing’s syndrome have been found
to be at increased risk of developing venous thromboem-
bolism, stroke, and myocardial infarction [49]. Many of
these are non-specific symptoms, and the manifestations of
Cushing’s disease overlap with many common conditions
including obesity, depression, and hypertension [32, 50].
In addition to this significant morbidity, untreated
Cushing’s disease is associated with excess mortality [49,
51]. Overall mortality in Cushing’s disease is double that of
the general population [52], and up to four times higher
than in age- and sex-matched controls [4, 49]. In addition,
mortality in patients with Cushing’s disease is more than
twice that in patients with non-functioning pituitary mac-
roadenomas even when these have been previously treated,
implying that even transient cortisol over-exposure con-
tributes to the increase in mortality [53].
Of note, even after successful treatment, the long-term
effects of hypercortisolism mean that patients in remission
can be affected by sustained deterioration of the cardio-
vascular system, bone remodeling, and cognitive function
[54–59]. Thus, management plans for the patients in
remission of Cushing’s disease should include strategies to
identify cognitive impairments and psychiatric disorders
and to evaluate cardiovascular risk [60].
Diagnosis of Cushing’s disease
Differential diagnosis is required for Cushing’s disease
because of the non-specific symptoms and manifestations
common to other conditions. Hypercortisolemia may be the
cause of cyclic Cushing’s syndrome, a disease character-
ized by rhythmic fluctuations in glucocorticoid production;
hypercortisolism secondary to a number of disorders, such
as alcoholism and primary psychiatric disease, may also
lead to the so-called pseudo-Cushing syndrome [61].
Patients with pseudo-Cushing syndrome might exhibit
some of the clinical features of hypercortisolism; however,
resolution of the underlying disease also results in disap-
pearance of the symptoms. However, Cushing’s disease is
three to four-times more common in women than men [2,
62], and the disease usually manifests in adulthood, with
the usual age at diagnosis 25–50 years [53]. Cushing’s
disease is rare in childhood [63].
Initially, testing to establish chronic hypercortisolism
and diagnose Cushing’s syndrome is recommended if
features such as osteoporosis, hypertension, type 2 diabetes
mellitus, or thin skin are present in patients younger than
expected [32, 50]; other atypical features (e.g., resistant
hypertension, osteoporosis without explanation despite
comprehensive testing for secondary causes, and depres-
sion resistant to drugs) should also be tested to assess
disease severity [8]. A diagnosis can be made if 24-h uri-
nary free cortisol (UFC) or late-night salivary cortisol
levels are elevated, if there is a loss of the circadian rhythm
of cortisol levels, and if there is a positive response to a
low-dose (1 mg) overnight dexamethasone suppression test
[6, 8, 50]. Once the clinical diagnosis has been established,
an etiological diagnosis is then required to determine
Cushing’s disease. This can be based on ACTH levels: if
morning ACTH levels are normal/equivocal, but late-
afternoon (after 16:00) plasma ACTH levels are higher
than 10 pg/mL (2 pmol/L), then ACTH-dependent Cush-
ing’s disease can be suspected; in addition, if CRH-stim-
ulated ACTH levels are elevated, then Cushing’s disease
can be also suspected [32, 50]. Similarly, blockade of
cortisol in response to a high-dose dexamethasone test can
assist in the differential diagnosis of Cushing’s disease [32,
50].
A Cushing’s disease diagnosis can then be confirmed
using imaging, petrosal sinus sampling, or further bio-
chemical tests [32, 50]. If pituitary magnetic resonance
imaging reveals adenoma, or the inferior petrosal sinus
ACTH:peripheral ACTH ratio is [3 following adminis-
tration of CRH, then Cushing’s disease can be confirmed.
However, bilateral inferior petrosal sinus sampling is an
invasive test, and non-invasive diagnostic tests may be
preferred. A multidetector computed tomography scan,
with a combination of unenhanced and dynamic scans, is
Endocrine (2014) 47:9–20 11
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useful to detect adrenal adenomas and thus assists in dif-
ferential diagnosis [64]. A recommended diagnostic algo-
rithm is available for Cushing’s disease based on the results
of biochemical tests for levels of cortisol (Fig. 2) [32, 50].
However, none of these tests is fully proven to be able to
distinguish all cases of Cushing’s disease from normal and/
or obese individuals. In addition, there is no consensus
regarding the diagnostic cut-offs related to these tests,
which remain in debate; we would like to emphasize that
cut-off values are always selected in an arbitrary manner
and depend on the methods used for the different assays.
The biochemical tests are, however, useful for identifying
sub-clinical Cushing’s disease in the absence of clinical
manifestations [65].
Controversies in Cushing’s disease diagnosis
The recommended tests for cortisol levels suffer from
several general limitations. False-positive or false-negative
results are common if single tests are used because cortisol
Fig. 2 Diagnostic algorithm for Cushing’s disease [based on 32, 50].
ACTH adrenocorticotropic hormone, CRH corticotropin-releasing
hormone, CT computed tomography, Dex dexamethasone, DST
dexamethasone suppression test, MRI magnetic resonance imaging,
UFC urinary free cortisol
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levels fluctuate in a circadian pattern with intermittent
release of corticotrophin. In addition, several steroid
medications affect cortisol levels, which influence the
accuracy of the results (Table 1) [66–76]. The common
diagnostic tests have different sensitivities and specificities,
and this, combined with the incidence of false-positives
and false-negatives, means that repeat testing or use of
several different tests is usually needed to provide a reli-
able diagnosis [77, 78]. With regard to test methodologies,
multiple protocols and different cutoff criteria often exist
for each test [79], and expertise is needed for accurate use
of the tests; thus, in routine clinical practice their perfor-
mance may be less than satisfactory [78, 80, 81]. However,
night-time salivary cortisol measures offer several benefits
over the 24-h UFC test for first-line screening [81, 82].
These include greater reproducibility and the non-invasive
nature of the test compared with 24-h UFC measurement.
Taking two samples rather than one increased the accuracy
of the late-night test [83].
Recommendations for the diagnosis and treatment
of Cushing’s disease
Recommendations for early diagnosis
Cushing’s syndrome is one of several disorders in which
there may be considerable difficulty and delay in diagnosis
[65]. In addition, the need for a differential diagnosis
contributes to difficulties in identifying patients with
Cushing’s disease. As a result, the mean time-to-diagnosis
interval for Cushing’s disease has been estimated to be as
high as 6 years [84]. However, early diagnosis can prompt
timely intervention, decreasing patient morbidity and
mortality [13], as well as a decrease in the rates of com-
plications associated with treatment [85]. Different cate-
gories of patients should undergo screening for Cushing’s
syndrome, in particular those with visceral obesity, buffalo
hump, diabetes mellitus, and hypertension, as well as those
with obesity, vertebral fractures, and patients presenting
with pituitary/adrenal incidentaloma. Salivary cortisol
could be a suitable screening test once robust reference
ranges are available. Another interesting screening test is
the cortisol level in hair [86], but the usefulness of this
method still needs to be confirmed in large populations.
The development of educational programs for physicians
(such as internists, cardiologists) aimed to meet patients
with Cushing’s disease, and new screening approaches
with ‘‘easy-to-use’’ and cheaper tests are needed.
Recommendations for treatment
The treatment goals in Cushing’s disease are the reversal of
clinical features, normalization of cortisol levels with
minimal morbidity, removal of the tumor mass, and/or
stabilization of tumor growth, while preserving pituitary
function and long-term control without recurrence [13].
Several interventions that can help achieve these goals are
available. As mentioned above, the first-line treatment in
Cushing’s disease is TSS to remove the adenoma, but its
success is dependent on surgeon experience and total
removal of the tumor tissue [13, 87, 88]; thus, success is
more likely in patients with microadenoma [89–95]. If the
initial surgery fails, repeat surgery may be necessary;
alternatively, radiotherapy is also an option if initial TSS is
unsuccessful. However, none of the surgical or radiother-
apeutic options is without risk (Table 2) [13, 21, 95, 96,
98]. Medical therapy can also be useful in cases when
initial surgery has failed [102], whereas bilateral adrenal-
ectomy—a highly invasive surgery that requires life-long
maintenance hormone replacement therapy—is an inter-
vention of last resort [13].
The state-of-the-art of medical therapy for Cushing’s
disease has recently advanced with the approval of pa-
sireotide in Europe and the US to treat adult patients with
Cushing’s disease for whom surgery is not an option or for
whom surgery has failed. Previously, the only medical
therapies used for Cushing’s disease were drugs inhibiting
steroidogenesis, such as ketoconazole, metyrapone, mito-
tane, and etomidate [13, 23]. These are directed at the
adrenal glands rather than at the primary cause of Cush-
ing’s disease, the ACTH-secreting pituitary adenoma, and
may also be limited by a delayed onset of action and/or
adverse events (Table 3) [13, 23, 103]. In contrast, pa-
sireotide is the first medical therapy specifically designed
and developed as a pituitary-targeted treatment for patients
with Cushing’s disease [104]. In the largest phase III trial
performed in patients with Cushing’s disease to date, pa-
sireotide was beneficial with respect to clinical and patient
quality-of-life outcomes over a period of 12 months [24].
In terms of safety, a high frequency of hyperglycemia was
Table 1 Medications associated with iatrogenic Cushing’s syndrome
Medication Use
Glucocorticoids [67–69] Chronic inflammatory
disease
Immunosuppression after
organ transplant
Inhaled corticosteroids (especially in
combination with ritonavir) [67, 69–71]
Asthma
Allergic rhinitis
Corticosteroid creams [67, 73–75] Atopic dermatitis
Psoriasis
Atopic eczema
Endocrine (2014) 47:9–20 13
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observed with pasireotide; other adverse events were sim-
ilar to those associated with other somatostatin analogs.
Furthermore, with over 2 years of treatment with pasireo-
tide, the normalization of UFC levels achieved in the first
year was sustained, while the adverse event profile
remained similar to that seen with 1 year of treatment [25].
Future directions and research
Despite the availability of diagnostic tests and recent pro-
gress in the treatments available for Cushing’s disease,
several challenges remain for those involved in patient care
and management. The controversies associated with the
Table 2 Surgical and radiotherapeutic treatment options for Cushing’s disease
TSS Repeat surgery Bilateral
adrenalectomy
Conventional
radiotherapy
Stereotactic
radiosurgery
Fractionated
stereotactic
radiation
therapy
Brachytherapy
Indication Traditional first-
line therapy
Following
unsuccessful
surgery
Non-response/
resistance to
medical
therapy/
radiotherapy
[13, 100]
Patients
declining
other therapy
[2] or with
low
likelihood of
successful
pituitary
surgery [100]
Option after
unsuccessful
TSS
May eliminate
tumors
beyond the
reach of TSS
(invading the
dura or
cavernous
sinus) [13]
Option after
unsuccessful
TSS
A Gamma Knife
can be used as a
primary
treatment in
patients who are
not good
candidates for
surgery [95]
Option after
unsuccessful
TSS
Option after
unsuccessful
TSS
Efficacy 65–90 %
microadenoma
[13]; \65 %
macroadenoma
[13]
37–73 % [96,
97]
Cortisol levels
lowered
immediately
in almost all
patients
Efficacy
similar to
surgery [13]
Remission
rate:
50–100 %
[95, 99]
The effects of
radiotherapy
may only
become
apparent after
many years
[20]
Remission rate:
63–100 %
(Gamma Knife),
90–94 %
(proton beam)
[95]
Remission
rate:
54–75 %
[13]
Remission rate:
75–100 % [98]
Induces remission
faster than other
forms of
radiotherapy/
radiosurgery
Success
factors
Experienced
surgeon [13]
Microadenoma
[13]
Long-term
surveillance
[14]
Confirmed
remaining
pituitary
adenoma
[101]
Confirmation
within
4–6 weeks of
initial
surgery [13]
Failure
factors/
risks
Younger age [13]
Macroadenoma
[13, 98]
Adenoma not
located [96]
Lower
remission
rates than
after first
surgery
May be
followed by
pituitary
deficiency or
failure [21]
Pituitary hormone
deficiency
develops in two-
thirds of patients
[95]
May be
followed by
pituitary
hormone
deficiency
[95]
May be followed
by pituitary
hormone
deficiency/
hypopituitarism
[95]
TSS transsphenoidal surgery
14 Endocrine (2014) 47:9–20
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currently available diagnostic tests mean that screening and
early identification of patients with Cushing’s disease
remains complex. Thus, simpler, more accurate diagnostic
tests are required to optimize differential diagnosis. Some
promising recent developments include the use of com-
bined quantification of UFC/cortisone and detection of
synthetic glucocorticoids [105]. Steroid treatment has been
reported as a cause of Cushing’s syndrome in some cases
[67], and thus the use of a liquid chromatography-tandem
mass spectrometry method to detect commonly prescribed
steroid drugs simultaneously with measurement of 24-h
UFC and cortisone could assist in the accurate diagnosis of
Cushing’s disease [106, 107]. As discussed above, the use
of salivary cortisol tests offers advantages over the 24-h
UFC test, and successful methods for automating analysis
of salivary cortisol levels have recently been reported,
increasing the clinical utility of this diagnostic test [108,
109].
The recent introduction of pasireotide has expanded the
range of therapeutic options available for the management
of patients with Cushing’s disease, allowing lowering of
ACTH secretion, normalization of cortisol production by
the adrenal glands, restoration of normal secretory
dynamics to the hypothalamic—pituitary—adrenal axis,
and inhibition of tumor growth [31]. Several other thera-
pies (directed to the pituitary as a target and steroidogen-
esis inhibitor therapies) have been investigated or are in
development for use in Cushing’s disease. However, these
have either not been extensively studied clinically or the
initial promise shown has not been fulfilled in further
investigations (Table 4) [110–119]. A promising product
currently in development is LCI699, a potent 11b-
hydroxylase inhibitor [118]. Preliminary results were pre-
sented at the 2012 Congress of the European NeuroEndo-
crine Association showing the efficacy and a satisfactory
safety profile in patients with Cushing’s disease treated
with this new compound [118]. In small-scale studies, ca-
bergoline monotherapy has shown efficacy in selected
patients with Cushing’s disease, but close follow-up was
required for dose adjustments [111, 112, 119]. In these
studies, the use of cabergoline was effective in the control
of cortisol secretion, measured via changes in UFC
excretion. However, additional large-scale prospective
studies are needed to establish cabergoline therapy in these
patients. Despite a response to bromocriptine in some cases
of Cushing’s disease, there is generally no reduction of
hypercortisolism seen in patients with Cushing’s disease
treated with this investigative agent [114, 120]. A molecule
with initially encouraging experimental results in Cush-
ing’s disease models or theoretical advantages over exist-
ing therapies is BIM-23A760. The chimeric BIM-23A760
molecule was investigated as a possible therapy on the
basis of its theoretically increased inhibition of ACTH
secretion from Cushing’s-causing corticotroph tumors
Table 3 Currently available medical treatment options for Cushing’s disease [13, 23, 103]
Mode of action Typical dose Characteristics Adverse events
Pituitary-directed somatostatin analog
Pasireotide 0.3 mg b.i.d to 0.9 mg b.i.d
(recommended starting dose
is 0.6 mg b.i.d)
Enhanced activity at the principal
receptor sub-type expressed in
the target gland
Hyperglycemia; diabetes mellitus; diarrhea, abdominal
pain, nausea; cholelithiasis; injection site reaction,
fatigue
Steroidogenesis inhibitor
Ketoconazole 200 mg b.i.d to 400 mg t.i.d Several weeks needed to see full
benefit
Reduced total cholesterol and low-
density lipoprotein cholesterol
Antiandrogenic properties; gynecomastia and reduced
libido in men
Gastrointestinal upset and skin rashes
Liver enzyme dysfunction in 10 % of cases
Metyrapone 250 mg q.i.d to 1,500 mg q.i.d Potent; rapid onset of action
Serum cortisol levels fall within
4 h of initial dose
Care needed to avoid over-
treatment
Nausea, abdominal pain
Accumulation of cortisol precursors results in elevated
androgens, leading to hirsutism and acne in women
Mitotane 500 mg t.i.d to 3,000 mg t.i.d Slow onset of action
Sustained action maintained after
discontinuation in up to 33 % of
patients
Needs gradual uptitration and to
be taken with food
At doses [2,000 mg/day, nausea, anorexia, and
diarrhea
At highest doses, adrenal insufficiency and neurological
adverse events, abnormal liver enzymes,
hypercholesterolemia, skin rash, hypouricaemia,
gynecomastia
The glucocorticoid-receptor antagonist mifepristone has been recently approved by the Food and Drug Administration in the US for the
management of hyperglycemia in patients with Cushing’s disease
b.i.d. twice daily, q.i.d. four times daily, t.i.d. three times daily
Endocrine (2014) 47:9–20 15
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relative to that of other molecules, thought to be due to its
dual action on somatostatin and dopamine receptors [121].
However, a metabolite of BIM-23A760 with dopaminergic
activity gradually accumulates in vivo and interferes with
the activity of the parent compound [116]. In terms of
novel therapies, recently, long-term treatment with retinoic
acid was shown to be beneficial and well-tolerated in 5 of 7
patients with Cushing’s disease [122]. Further research into
pituitary-directed treatments for patients with Cushing’s
disease may yield additional medicinal therapies to extend
the clinical armamentarium available to physicians.
In addition to these pituitary-directed molecules, the
glucocorticoid receptor has been targeted in research aimed
at identifying novel therapies for Cushing’s disease. Mi-
fepristone is a glucocorticoid-receptor antagonist shown to
produce clinical and metabolic benefits in patients with
Cushing’s disease over 6 months [123]. However, a lack of
available biological monitoring data during treatment and a
risk of worsening of hypokalemia and blood pressure levels
mean that its clinical utility is limited to the management of
hyperglycemia in patients with Cushing’s disease [124–
126]. Mifepristone has been recently approved by the Food
and Drug Administration in the US for the treatment
of hyperglycemia in patients with Cushing’s disease.
Combination treatments with cabergoline and ketocon-
azole have also been reported; however, larger studies are
needed to determine the efficacy and safety of these
therapies.
Conclusions
In summary, Cushing’s disease is the most common cause
of endogenous Cushing’s syndrome, and is caused by
ACTH-secreting pituitary adenomas. It is associated with
significant complications and reduced quality of life, and is
a fatal condition in the absence of adequate treatment. The
diagnosis and treatment of patients with Cushing’s disease
are complex and require both a multidisciplinary and
individualized approach to patient management. Currently,
the first-line therapy in Cushing’s disease is TSS to remove
the adenoma. The recent approval of pasireotide, the first
medical therapy to directly target the cause of Cushing’s
disease, provides a new therapeutic option for patients in
whom initial TSS is unsuccessful or for those patients who
are ineligible for surgery.
Greater awareness of Cushing’s disease is required
among primary physicians because there is a high rate of
subclinical disease. The lack of awareness coupled with
signs and symptoms common to other conditions means
that more accurate diagnostic tests to screen for and diag-
nose Cushing’s disease in its earliest stages are required.
Table 4 Medical therapies in development for Cushing’s disease
Compound Class Rationale Available evidence
Pituitary-directed therapies
Cabergoline Dopamine
receptor
agonist
D2 receptor expressed in [75 % of
corticotrophic pituitary adenomas and
associated with inhibitory function [111]
May not be greatly downregulated in the
presence of glucocorticoids [112]
Small, short-term study: cabergoline may be effective
in a subset of patients with Cushing’s disease [111]
Small study (n = 20): cabergoline controls UFC levels
in post-surgical patients [112]
Bromocriptine Dopamine
receptor
agonist
D2 receptor expressed in [75 % of
corticotrophic pituitary adenomas and
associated with inhibitory function [112]
May not be greatly downregulated in the
presence of glucocorticoids [113]
ACTH secretion inhibited in vitro [113]
No reduction of hypercortisolism seen in patients with
Cushing’s disease [114]
BIM-23A760 Chimeric D2-and
sst2,5-
preferring
agonist
D2 receptor expressed in [75 % of
corticotrophic pituitary adenomas and
associated with inhibitory function [111]
May not be greatly downregulated in the
presence of glucocorticoids [112]
In theory, greater inhibitory effect due to possible D2
and somatostatin receptor dimer formation [115,
116]
Steroidogenesis inhibitor
LCI699 11b-hydroxylase
inhibitor
11b-hydroxylase catalyzes the final step of
cortisol synthesis
Proof-of-concept study: 12 patients were enrolled and
completed the study. The primary endpoint
(UFC B ULN or a C50 % decrease from baseline at
day 70) was achieved in 12 patients. No serious
drug-related adverse events were reported [118]
PPAR-c peroxisome proliferator-activated receptor gamma, UFC urinary free cortisol, ULN, upper limit of normal
16 Endocrine (2014) 47:9–20
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Future research into Cushing’s disease diagnosis and an
expanding number of treatment options will improve
clinical outcomes for patients with Cushing’s disease and
optimize their management.
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